Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
14.05
+0.09 (0.61%)
Nov 4, 2024, 1:09 PM EST - Market open

Takeda Pharmaceutical Income Statement

Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Sep '24 Mar '24 Mar '23 Mar '22 Mar '21 Mar '20 2019 - 2015
Revenue
4,546,0834,263,7624,027,4783,569,0063,197,8123,291,188
Upgrade
Revenue Growth (YoY)
9.43%5.87%12.85%11.61%-2.84%56.93%
Upgrade
Cost of Revenue
1,548,0741,431,5051,253,1631,127,3081,013,6551,120,146
Upgrade
Gross Profit
2,998,0092,832,2572,774,3152,441,6982,184,1572,171,042
Upgrade
Selling, General & Admin
1,091,0661,053,819997,234886,327875,514964,268
Upgrade
Research & Development
725,957728,617633,325526,087455,765492,088
Upgrade
Other Operating Expenses
-17,73235,05938,98710,43323,60210,663
Upgrade
Operating Expenses
2,344,3842,339,0202,154,6481,841,6361,760,1101,874,362
Upgrade
Operating Income
653,625493,237619,667600,062424,047296,680
Upgrade
Interest Expense
-119,122-115,392-116,973-122,432-130,806-149,010
Upgrade
Interest & Investment Income
21,40111,6285,7814,7632,15312,646
Upgrade
Earnings From Equity Investments
3,6196,473-8,630-15,36776-23,987
Upgrade
Currency Exchange Gain (Loss)
-13,612-13,612-9,729-3,903-15,57510,979
Upgrade
Other Non Operating Income (Expenses)
-30,814-31,5203,975-26,1191,118-10,631
Upgrade
EBT Excluding Unusual Items
515,097350,814494,091437,004281,013136,677
Upgrade
Merger & Restructuring Charges
-104,487-81,358-59,234-83,836-115,875-181,831
Upgrade
Gain (Loss) on Sale of Investments
-18,320-22,4168,482--
Upgrade
Gain (Loss) on Sale of Assets
14,0757,9758,9018,164235,11719,871
Upgrade
Asset Writedown
-51,821-139,809-62,484-54,421-17,521-60,974
Upgrade
Legal Settlements
-45,212-45,212-16,455-20,319-17,401-
Upgrade
Other Unusual Items
-39,619-39,619-12,1457,49790217,224
Upgrade
Pretax Income
269,71352,791375,090302,571366,235-60,754
Upgrade
Income Tax Expense
-20,454-91,40658,05272,405-9,936-105,044
Upgrade
Earnings From Continuing Operations
290,167144,197317,038230,166376,17144,290
Upgrade
Minority Interest in Earnings
-171-130-21-107-166-49
Upgrade
Net Income
289,996144,067317,017230,059376,00544,241
Upgrade
Net Income to Common
289,996144,067317,017230,059376,00544,241
Upgrade
Net Income Growth
51.33%-54.56%37.80%-38.81%749.90%-67.28%
Upgrade
Shares Outstanding (Basic)
1,5721,5641,5521,5641,5621,557
Upgrade
Shares Outstanding (Diluted)
1,5931,5801,5701,5771,5741,566
Upgrade
Shares Change (YoY)
1.07%0.67%-0.46%0.23%0.47%61.98%
Upgrade
EPS (Basic)
184.4792.09204.29147.14240.7228.41
Upgrade
EPS (Diluted)
182.0191.16201.94145.87238.9628.25
Upgrade
EPS Growth
49.73%-54.86%38.44%-38.96%745.88%-79.80%
Upgrade
Free Cash Flow
677,776540,924836,499999,853899,725542,670
Upgrade
Free Cash Flow Per Share
425.38342.28532.85633.95571.79346.49
Upgrade
Dividend Per Share
192.000188.000180.000180.000180.000180.000
Upgrade
Dividend Growth
4.35%4.44%0%0%0%0%
Upgrade
Gross Margin
65.95%66.43%68.88%68.41%68.30%65.97%
Upgrade
Operating Margin
14.38%11.57%15.39%16.81%13.26%9.01%
Upgrade
Profit Margin
6.38%3.38%7.87%6.45%11.76%1.34%
Upgrade
Free Cash Flow Margin
14.91%12.69%20.77%28.01%28.14%16.49%
Upgrade
EBITDA
1,328,5611,137,6981,210,6501,183,213983,718880,329
Upgrade
EBITDA Margin
29.22%26.68%30.06%33.15%30.76%26.75%
Upgrade
D&A For EBITDA
674,936644,461590,983583,151559,671583,649
Upgrade
EBIT
653,625493,237619,667600,062424,047296,680
Upgrade
EBIT Margin
14.38%11.57%15.39%16.81%13.26%9.01%
Upgrade
Effective Tax Rate
--15.48%23.93%--
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.